Compare Citius Pharmaceuticals Inc (CTXR) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs PAGSEG Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while PAGSEG Inc trades at $11.13 (market cap $2.94B). The key difference: PAGSEG Inc is far larger — about 215.9× Citius Pharmaceuticals Inc's market cap, and PAGSEG Inc pays a 10.49% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and PAGSEG Inc for 26 Days on average.
| CTXR | PAGS | |
|---|---|---|
Market Cap | $13.62M | $2.94B |
Volume | 132,438 | 4,242,708 |
Sector | Health | Industrials |
52-Week High | $1.82 | $12.00 |
52-Week Low | $0.48 | $8.44 |
Typical Hold Time | 16 Days | 26 Days |
Enterprise Value | $3.79M | $11.02B |
Dividend Yield | — | 10.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
PAGS trades at $11.13, up 5.9% in the last 24 hours, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 7.1 and robust profitability, including a 10.45% net income margin. Recent earnings beat expectations in Q2 2026, and the company maintains a solid dividend yield, supported by positive cash flow from operations of $7.56B in 2025.
The outlook for PAGS is positive, driven by undervaluation and earnings growth potential, but risks include macroeconomic pressures in Brazil and increased credit losses. Analyst consensus is strongly bullish with a $10.70 price target, though near-term volatility may persist due to mixed technical oscillators and competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
